Global Antidiabetic Drug Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones), By Application (Type I Diabetes, Type II Diabetes) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Antidiabetic Drug Market research report which is segmented by Types (Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones), By Applications (Type I Diabetes, Type II Diabetes), By Players/Companies Sanofi-Aventis, Eli Lilly, Oramed, Takeda, Boehringer Ingelheim, Novo Nordisk, Halozyme Therapeutics, Bristol-Myers Squibb, Pfizer, Tonghua Dongbao, Biocon, Wockhardt”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Antidiabetic Drug Market Research Report |
| By Type | Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones |
| By Application | Type I Diabetes, Type II Diabetes |
| By Companies | Sanofi-Aventis, Eli Lilly, Oramed, Takeda, Boehringer Ingelheim, Novo Nordisk, Halozyme Therapeutics, Bristol-Myers Squibb, Pfizer, Tonghua Dongbao, Biocon, Wockhardt |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 211 |
| Number of Tables & Figures | 148 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Antidiabetic Drug Market Report Segments:
The market is segmented by Type Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones and By Application Type I Diabetes, Type II Diabetes.
Some of the companies that are profiled in this report are:
- Sanofi-Aventis
- Eli Lilly
- Oramed
- Takeda
- Boehringer Ingelheim
- Novo Nordisk
- Halozyme Therapeutics
- Bristol-Myers Squibb
- Pfizer
- Tonghua Dongbao
- Biocon
- Wockhardt
Antidiabetic Drug Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Antidiabetic Drug Market
Overview of the regional outlook of the Antidiabetic Drug Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Antidiabetic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Antidiabetic Drug Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Alpha-Glucosidase Inhibitors
2. Biguanides, Sulphonylureas
3. Glp-1 Agonist
4. Meglitinides
5. Dpp-4 Inhibitors
6. Sglt–2
7. Thiazolodinediones
7. By Application:1. Type I Diabetes
2. Type II Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antidiabetic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Antidiabetic Drug Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antidiabetic Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antidiabetic Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antidiabetic Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antidiabetic Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antidiabetic Drug Market Size & Forecast, 2018-2028
4.5.1 Antidiabetic Drug Market Size and Y-o-Y Growth
4.5.2 Antidiabetic Drug Market Absolute $ Opportunity
Chapter 5 Global Antidiabetic Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antidiabetic Drug Market Size Forecast by Type
5.2.1 Alpha-Glucosidase Inhibitors
5.2.2 Biguanides
5.2.3 Sulphonylureas
5.2.4 Glp-1 Agonist
5.2.5 Meglitinides
5.2.6 Dpp-4 Inhibitors
5.2.7 Sglt–2
5.2.8 Thiazolodinediones
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antidiabetic Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antidiabetic Drug Market Size Forecast by Applications
6.2.1 Type I Diabetes
6.2.2 Type II Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antidiabetic Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antidiabetic Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antidiabetic Drug Analysis and Forecast
9.1 Introduction
9.2 North America Antidiabetic Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antidiabetic Drug Market Size Forecast by Type
9.6.1 Alpha-Glucosidase Inhibitors
9.6.2 Biguanides
9.6.3 Sulphonylureas
9.6.4 Glp-1 Agonist
9.6.5 Meglitinides
9.6.6 Dpp-4 Inhibitors
9.6.7 Sglt–2
9.6.8 Thiazolodinediones
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antidiabetic Drug Market Size Forecast by Applications
9.10.1 Type I Diabetes
9.10.2 Type II Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antidiabetic Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Antidiabetic Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antidiabetic Drug Market Size Forecast by Type
10.6.1 Alpha-Glucosidase Inhibitors
10.6.2 Biguanides
10.6.3 Sulphonylureas
10.6.4 Glp-1 Agonist
10.6.5 Meglitinides
10.6.6 Dpp-4 Inhibitors
10.6.7 Sglt–2
10.6.8 Thiazolodinediones
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antidiabetic Drug Market Size Forecast by Applications
10.10.1 Type I Diabetes
10.10.2 Type II Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antidiabetic Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antidiabetic Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antidiabetic Drug Market Size Forecast by Type
11.6.1 Alpha-Glucosidase Inhibitors
11.6.2 Biguanides
11.6.3 Sulphonylureas
11.6.4 Glp-1 Agonist
11.6.5 Meglitinides
11.6.6 Dpp-4 Inhibitors
11.6.7 Sglt–2
11.6.8 Thiazolodinediones
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antidiabetic Drug Market Size Forecast by Applications
11.10.1 Type I Diabetes
11.10.2 Type II Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antidiabetic Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Antidiabetic Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antidiabetic Drug Market Size Forecast by Type
12.6.1 Alpha-Glucosidase Inhibitors
12.6.2 Biguanides
12.6.3 Sulphonylureas
12.6.4 Glp-1 Agonist
12.6.5 Meglitinides
12.6.6 Dpp-4 Inhibitors
12.6.7 Sglt–2
12.6.8 Thiazolodinediones
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antidiabetic Drug Market Size Forecast by Applications
12.10.1 Type I Diabetes
12.10.2 Type II Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antidiabetic Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Type
13.6.1 Alpha-Glucosidase Inhibitors
13.6.2 Biguanides
13.6.3 Sulphonylureas
13.6.4 Glp-1 Agonist
13.6.5 Meglitinides
13.6.6 Dpp-4 Inhibitors
13.6.7 Sglt–2
13.6.8 Thiazolodinediones
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Applications
13.10.1 Type I Diabetes
13.10.2 Type II Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antidiabetic Drug Market: Competitive Dashboard
14.2 Global Antidiabetic Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi-Aventis
14.3.2 Eli Lilly
14.3.3 Oramed
14.3.4 Takeda
14.3.5 Boehringer Ingelheim
14.3.6 Novo Nordisk
14.3.7 Halozyme Therapeutics
14.3.8 Bristol-Myers Squibb
14.3.9 Pfizer
14.3.10 Tonghua Dongbao
14.3.11 Biocon
14.3.12 Wockhardt
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antidiabetic Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antidiabetic Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antidiabetic Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antidiabetic Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antidiabetic Drug Market Size & Forecast, 2018-2028
4.5.1 Antidiabetic Drug Market Size and Y-o-Y Growth
4.5.2 Antidiabetic Drug Market Absolute $ Opportunity
Chapter 5 Global Antidiabetic Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antidiabetic Drug Market Size Forecast by Type
5.2.1 Alpha-Glucosidase Inhibitors
5.2.2 Biguanides
5.2.3 Sulphonylureas
5.2.4 Glp-1 Agonist
5.2.5 Meglitinides
5.2.6 Dpp-4 Inhibitors
5.2.7 Sglt–2
5.2.8 Thiazolodinediones
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antidiabetic Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antidiabetic Drug Market Size Forecast by Applications
6.2.1 Type I Diabetes
6.2.2 Type II Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antidiabetic Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antidiabetic Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antidiabetic Drug Analysis and Forecast
9.1 Introduction
9.2 North America Antidiabetic Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antidiabetic Drug Market Size Forecast by Type
9.6.1 Alpha-Glucosidase Inhibitors
9.6.2 Biguanides
9.6.3 Sulphonylureas
9.6.4 Glp-1 Agonist
9.6.5 Meglitinides
9.6.6 Dpp-4 Inhibitors
9.6.7 Sglt–2
9.6.8 Thiazolodinediones
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antidiabetic Drug Market Size Forecast by Applications
9.10.1 Type I Diabetes
9.10.2 Type II Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antidiabetic Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Antidiabetic Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antidiabetic Drug Market Size Forecast by Type
10.6.1 Alpha-Glucosidase Inhibitors
10.6.2 Biguanides
10.6.3 Sulphonylureas
10.6.4 Glp-1 Agonist
10.6.5 Meglitinides
10.6.6 Dpp-4 Inhibitors
10.6.7 Sglt–2
10.6.8 Thiazolodinediones
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antidiabetic Drug Market Size Forecast by Applications
10.10.1 Type I Diabetes
10.10.2 Type II Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antidiabetic Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antidiabetic Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antidiabetic Drug Market Size Forecast by Type
11.6.1 Alpha-Glucosidase Inhibitors
11.6.2 Biguanides
11.6.3 Sulphonylureas
11.6.4 Glp-1 Agonist
11.6.5 Meglitinides
11.6.6 Dpp-4 Inhibitors
11.6.7 Sglt–2
11.6.8 Thiazolodinediones
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antidiabetic Drug Market Size Forecast by Applications
11.10.1 Type I Diabetes
11.10.2 Type II Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antidiabetic Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Antidiabetic Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antidiabetic Drug Market Size Forecast by Type
12.6.1 Alpha-Glucosidase Inhibitors
12.6.2 Biguanides
12.6.3 Sulphonylureas
12.6.4 Glp-1 Agonist
12.6.5 Meglitinides
12.6.6 Dpp-4 Inhibitors
12.6.7 Sglt–2
12.6.8 Thiazolodinediones
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antidiabetic Drug Market Size Forecast by Applications
12.10.1 Type I Diabetes
12.10.2 Type II Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antidiabetic Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Type
13.6.1 Alpha-Glucosidase Inhibitors
13.6.2 Biguanides
13.6.3 Sulphonylureas
13.6.4 Glp-1 Agonist
13.6.5 Meglitinides
13.6.6 Dpp-4 Inhibitors
13.6.7 Sglt–2
13.6.8 Thiazolodinediones
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Applications
13.10.1 Type I Diabetes
13.10.2 Type II Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antidiabetic Drug Market: Competitive Dashboard
14.2 Global Antidiabetic Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi-Aventis
14.3.2 Eli Lilly
14.3.3 Oramed
14.3.4 Takeda
14.3.5 Boehringer Ingelheim
14.3.6 Novo Nordisk
14.3.7 Halozyme Therapeutics
14.3.8 Bristol-Myers Squibb
14.3.9 Pfizer
14.3.10 Tonghua Dongbao
14.3.11 Biocon
14.3.12 Wockhardt
Segments Covered in the Report
The global Antidiabetic Drug market has been segmented based on
By Types
The global Antidiabetic Drug market has been segmented based on
By Types
- Alpha-Glucosidase Inhibitors
- Biguanides, Sulphonylureas
- Glp-1 Agonist
- Meglitinides
- Dpp-4 Inhibitors
- Sglt–2
- Thiazolodinediones
- Type I Diabetes
- Type II Diabetes
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Sanofi-Aventis
- Eli Lilly
- Oramed
- Takeda
- Boehringer Ingelheim
- Novo Nordisk
- Halozyme Therapeutics
- Bristol-Myers Squibb
- Pfizer
- Tonghua Dongbao
- Biocon
- Wockhardt
Our Clients
Related Reports
Some other reports from this category!
